Insurance companies are buying back their own stock in hordes. Maybe they shouldn't

Chubb authorized a new $7.5 billion share repurchase program, while Travelers earlier approved a $5 billion buyback, lifting its repurchase capacity to $7 billion. Bank of America analysts warned that insurers buying back stock at 2-3x book value may destroy long-term shareholder value even if EPS rises in the near term. The note contrasts today’s expensive repurchases with periods when buybacks were done at or below book value, highlighting capital-allocation risk in a softening insurance market.

Analysis

The market is treating insurer buybacks as a simple EPS lever, but the more important signal is that managements are implicitly choosing to shrink the equity base rather than accelerate growth. In a softening pricing environment, that can mask a deteriorating underwriting cycle for several quarters, yet it also exposes the higher-quality franchises: firms buying back stock above intrinsic value are effectively admitting organic opportunities are scarce. The second-order effect is a widening dispersion between insurers with true excess capital and those using capital returns to defend headline growth.

BofA’s critique matters most for names trading well above normalized book because the economic hurdle rate of repurchases is now much higher than in prior cycles. At 2-3x book, every dollar spent on stock is a claim on future compounding that could have been retained for underwriting expansion, catastrophe volatility, or opportunistic M&A if pricing deteriorates further. That makes the key variable not authorization size, but whether the market rewards short-term EPS accretion long enough to offset the long-term dilution of intrinsic capital.

The best-positioned names are the ones buying below book or substituting dividends for repurchases when valuation is stretched. RNR looks relatively better on that frame because its capital return policy appears more valuation-aware, while CB is more exposed to being penalized if buybacks continue at elevated multiples and the market stops paying up for optics. BAC is not an insurer, but its sell-side call is useful as a sector tell: this is a positioning debate about capital discipline, not just payout optics, and that tends to persist for months until underwriting results or price-to-book reset the narrative.

The contrarian view is that the market may be underestimating how long buybacks can prop per-share metrics in a stagnant growth environment, especially if rates remain supportive and loss activity stays benign. The real risk is a valuation unwind: if book multiples compress in a downturn, the companies currently repurchasing stock at premium valuations will have permanently reduced financial flexibility just when it becomes most valuable. That asymmetry argues for favoring insurers with explicit capital return frameworks tied to valuation, not discretionary repurchase programs justified by confidence language.

Key Decisions for Investors

• Long RNR / short CB as a 3-6 month relative-value pair: own the insurer with more valuation-aware capital returns versus the one most exposed to buyback-over-book criticism. Target 5-8% spread capture; stop out if CB re-rates below its recent book multiple trend or RNR underperforms on underwriting.
• Buy BAC puts or run a short-risk reversal into the next insurer earnings cycle as a hedge against a sector multiple reset. This is a lower-conviction but cleaner expression of the thesis that the sell-side is early on capital-destruction risk.
• Avoid chasing fresh long exposure in insurers announcing large repurchase authorizations at >2x book; wait for either a valuation pullback or a catalyst confirming underwriting momentum. Risk/reward is poor because upside is already being front-loaded into EPS optics.
• Prefer insurers returning capital via dividends over aggressive buybacks when trading above normalized book; use that lens to screen for quality within the sector over the next 1-2 quarters. This should outperform if the market rotates from growth optics to intrinsic-capital discipline.
• If you want directional exposure, consider a small tactical short in the most expensive repurchase-heavy insurer basket for 1-2 quarters, with downside capped by the possibility that management commentary sustains sentiment. Best entry is on post-earnings strength, not weakness, to maximize asymmetry.